Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Is the alpha-galactosidase A variant p.Asp313Tyr (p.D313Y) pathogenic for Fabry disease? A systematic review

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Titrating a modified ketogenic diet for patients with McArdle disease: A pilot study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Increased risk of sudden death in untreated Primary Carnitine Deficiency

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Long-term prognosis following hospitalization for acute myocarditis - a matched nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Thyroid function in COVID-19 and the association with cytokine levels and mortality

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Prevalence of Pathogenic Germline DICER1 Variants in Young Individuals Thyroidectomised Due to Goitre - A National Danish Cohort

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Incidence and impact of parvovirus B19 infection in seronegative solid organ transplant recipients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

The identification of pathogenic GLA variants plays a central role in the establishment of a definite Fabry disease (FD) diagnosis. We aimed to review and interpret the published data on the p.Asp313Tyr (p.D313Y) variant pathogenicity and clinical relevance. We performed a systematic review of peer-reviewed publications and case-reports on individuals and populations harbouring the p.Asp313Tyr variant. Overall, 35 studies were included in this review. We collected data regarding the clinical manifestations, alpha-galactosidase A enzyme activity, levels of the biomarkers globotriaosylceramide (Gb3 ) and sphingosine-globotriaosylceramide (lyso-Gb3 ) and histological findings of p.Asp313Tyr carriers. The prevalence of p.Asp313Tyr in populations at risk for FD (kidney, heart, neurologic disorders, or symptomatic populations) was calculated. We found high residual enzyme activity, low frequency of clinical features specific for FD, non-elevated lysoGb3 /Gb3 concentrations and lack of intracellular Gb3 accumulation in biopsies in the p.Asp313Tyr carriers. The prevalence of the variant in populations at risk for FD was comparable to the reported frequency in the general population. A possible higher frequency was only observed in neurologic disorders. p.Asp313Tyr can be classified as neutral or variant of unknown significance. Further investigations will be helpful to clarify a possible association between the variant and manifestations in the brain vessels.

OriginalsprogEngelsk
TidsskriftJournal of Inherited Metabolic Disease
Vol/bind43
Udgave nummer5
Sider (fra-til)922-933
Antal sider12
ISSN0141-8955
DOI
StatusUdgivet - sep. 2020

Bibliografisk note

© 2020 SSIEM.

ID: 59998002